Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer - Wikidata - wikimedia - TriplyDB

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

http://www.wikidata.org/entity/Q34967515

about

Monitoring serum HER2 levels in breast cancer patients.The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.Effect of Fu-Zheng-Xiao-Liu Granules on Expression of Human Epidermal Growth Factor Receptor 2 (HER-2) and Proliferation and Apoptosis of Breast Cancer Cell Line SKBR-3.Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer.

P2860

Q35686002-985ED0E8-47B9-4DB6-A34D-D8B52293224C Q36153924-19DE6720-00C5-467F-B086-EF971D280579 Q37367705-436FA160-C89B-4E4B-959E-09F4FF688D49 Q37551185-1B0D7935-0943-4E0D-899E-4AC79C9EB015 Q38573871-0FE3BC4E-5A07-4D71-B4B8-4D6D489C4812 Q38661390-26FFBCC8-EB75-4DE0-B826-4BE4BB29DC29 Q49787807-3FD4BA44-249C-4DDD-BF68-B7DD75C160B4

P2860

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

http://www.wikidata.org/entity/Q34967515

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@ast

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@en

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@nl

type

label

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@ast

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@en

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@nl

prefLabel

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@ast

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@en

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@nl

P1433

Q34967515-64081BBB-CE95-4E2A-A27D-FE379B59FBB3

P1476

Q34967515-24A58145-B908-47BA-A858-4741A6D63706

P2093

Q34967515-04CCC6A9-1337-46E5-B5A6-C3FFECD30C00

Q34967515-06897326-5914-4A6D-9800-49B811692FA0

Q34967515-128C5318-6251-4E4D-8004-1869A5A4ABF8

Q34967515-28E2A175-8810-46C0-9DD1-9F883288C558

Q34967515-43468664-E2E3-487E-8360-7FF59938C8E7

Q34967515-44069A10-5FFF-454C-9F44-F7CA6D853A0A

Q34967515-67A6D3F7-3C20-48FE-BE33-337867C2ACDA

Q34967515-6ED5E781-47BE-4D38-8F9D-144D8AE97B1B

Q34967515-81D03F99-BA5A-4633-856E-03EC94EE4A4A

Q34967515-82F5FC60-4731-42C8-9A30-D818490B4C56

P2860

Q34967515-15F26229-EBA8-4D1E-A809-6BAC630D45EA

Q34967515-23CB2317-F3A4-40E3-8C5C-529D682149E0

Q34967515-2487B567-580D-4B1C-B01E-655A65E6AD43

Q34967515-32020EDD-65F2-40A5-9B5E-0EF25EABC123

Q34967515-396AB079-A7A4-408C-8D4C-4F97CE7554A4

Q34967515-396DE00C-2732-44C8-952F-967450F3C597

Q34967515-5D563FD5-E67E-43E3-808D-543EBCD93E54

Q34967515-6723D1E0-6914-4C9C-A688-B34DB086D3FD

Q34967515-6D6361B4-7DC0-450D-B5E3-5A50F5FD37A7

Q34967515-70210224-D7D3-4E2D-8142-19E271BA8FC5

P2888

Q34967515-F1375952-D248-4213-9962-0EB03A3305F9

P304

Q34967515-3A9B2E81-57CE-4555-B19B-BD973C58FFD2

P31

Q34967515-B447B257-B0F6-4E17-B214-804C96C37228

P356

Q34967515-95A7DC2F-7AD6-4066-910F-74C0CD8C3F3B

P407

Q34967515-5B5C50F8-57E9-4D69-8BBA-25DD7242885D

P478

Q34967515-172DC18D-AFB8-4E5D-A778-500357D15A8B

P577

Q34967515-6165F770-F2E3-4104-8ED9-EE221D90FBDC

P5875

Q34967515-26752E2D-90E0-46D3-A4F2-AC2BE83DEA8C

P6179

Q34967515-D8D30B83-0D51-42DC-9AAF-477302D21A22

P698

Q34967515-2085147F-88F7-4502-9F41-3B5120BDEC42

P932

Q34967515-B4B070E1-6D97-415A-9F97-6CA3CCF73816

P356

1471-2407-14-929

P1433

P1476

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

@en

P2093

Beom Seok Ko

http://www.w3.org/2001/XMLSchema#string

Byung Ho Son

http://www.w3.org/2001/XMLSchema#string

Gyungyub Gong

http://www.w3.org/2001/XMLSchema#string

Hee Jeong Kim

http://www.w3.org/2001/XMLSchema#string

Hee Jin Lee

http://www.w3.org/2001/XMLSchema#string

Jin-Hee Ahn

http://www.w3.org/2001/XMLSchema#string

Jong Han Yu

http://www.w3.org/2001/XMLSchema#string

Jong Won Lee

http://www.w3.org/2001/XMLSchema#string

Joohon Sung

http://www.w3.org/2001/XMLSchema#string

Kyung Hae Jung

http://www.w3.org/2001/XMLSchema#string

P2860

Challenges in the clinical utility of the serum test for HER2 ECD

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Measuring HER-2 in breast cancer. Immunohistochemistry, FISH, or ELISA?

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

Serum HER-2 concentration in patients with primary breast cancer.

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients.

P2888

1471-2407-14-929

P304

929

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-929

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269467046

http://www.w3.org/2001/XMLSchema#string

P6179

1045347614

http://www.w3.org/2001/XMLSchema#string

P698

25491647

http://www.w3.org/2001/XMLSchema#string

P932

4295268

http://www.w3.org/2001/XMLSchema#string